Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 11Colorectal Neoplasms 4Breast Neoplasms 3Solid Tumors 2Sarcoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Gastrointestinal Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Triple Negative Breast Neoplasms 1Recurrence 1Neuroendocrine Tumors 1Neoplasms 1Liver Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Glioblastoma 1Gallbladder Neoplasms 1Disease Progression 1Disease 1Clear-cell metastatic renal cell carcinoma 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Neuroendocrine 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1Advanced Adult Hepatocellular Carcinoma 1

Interventions

Lenalidomide 4Gemcitabine 4Dexamethasone 4Cyclophosphamide 4Bortezomib 4Nivolumab 3Cisplatin 3Carboplatin 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2pomalidomide 2pembrolizumab 2liposomal doxorubicin 2fludarabine 2durvalumab 2capivasertib 2Paclitaxel 2Doxorubicin 2Bevacizumab 2venetoclax 1umbralisib 1ublituximab 1tremelimumab 1tivozanib 1ricolinostat 1regorafenib 1pazopanib 1niraparib 1nilotinib 1neratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Disease Progression × tivozanib × Clear all
NCT04987203 2026-05-08

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc.

Phase 3 Completed
343 enrolled
Genitourinary

Carcinoma, Renal Cell, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡